Harvard Bioscience, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 10, 2026, reporting financial results for both the three and nine months ended on that date.

Key Highlights

  • Nine-month net loss of $8,957 thousand: The company reported a net loss of $8,957 thousand for the nine months ended September 30, 2026, compared to a net loss of $53,853 thousand in the same period of 2025, which included a goodwill impairment charge of $47,951 thousand.
  • Q3 2026 revenues of $22,196 thousand: Quarterly revenues rose to $22,196 thousand from $20,591 thousand in Q3 2025, according to the filing.
  • Basic and diluted loss per share of $0.58: For the three months ended September 30, 2026, the company reported a loss per share of $0.58, compared to $0.28 in Q3 2025, retroactively adjusted to reflect the 1-for-10 reverse stock split effective March 13, 2026.
  • Total stockholders' equity declined to $5,105 thousand: Stockholders' equity fell from $13,734 thousand at December 31, 2025, to $5,105 thousand at September 30, 2026, driven by the net loss for the period.
  • Long-term debt increased to $37,153 thousand: Long-term debt, net, rose from $35,870 thousand at December 31, 2025, to $37,153 thousand at September 30, 2026.
  • 4,573,080 shares outstanding as of November 3, 2026: The share count reflects the 1-for-10 reverse stock split that became effective March 13, 2026, with post-split trading beginning March 16, 2026.

Harvard Bioscience Q3 2026 Financial Results: Revenue Growth Amid Continued Net Losses

According to the filing, Harvard Bioscience (NASDAQ:HBIO) reported revenues of $22,196 thousand for the three months ended September 30, 2026, an increase from $20,591 thousand in the comparable prior-year quarter. For the nine months ended September 30, 2026, revenues totaled $65,678 thousand, up from $62,815 thousand in the first nine months of 2025. Gross profit for the nine-month period was $37,181 thousand, compared to $35,738 thousand in the same period of 2025.

The company disclosed a net loss of $2,623 thousand for Q3 2026, compared to a net loss of $1,231 thousand in Q3 2025. For the nine-month period, the net loss was $8,957 thousand versus $53,853 thousand in the first nine months of 2025. The 2025 nine-month figure included a goodwill impairment charge of $47,951 thousand, which did not recur in 2026. Interest expense for the nine months ended September 30, 2026, was reported as $5,304 thousand, up from $3,257 thousand in the same period of 2025.

The condensed consolidated balance sheet as of September 30, 2026, showed total assets of $75,299 thousand and total liabilities of $70,194 thousand, leaving total stockholders' equity of $5,105 thousand. Cash and cash equivalents stood at $4,856 thousand, down from $8,614 thousand at December 31, 2025. The accumulated deficit reached $223,667 thousand as of September 30, 2026, compared to $214,710 thousand at December 31, 2025. During the nine-month period, the company recorded stock-based compensation of $1,073 thousand and received $150 thousand from warrant exercises.

What Was Disclosed

Harvard Bioscience filed its quarterly report covering the period ended September 30, 2026, disclosing revenues, net losses, balance sheet data, and equity changes, including the effect of the 1-for-10 reverse stock split that became effective March 13, 2026.